Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial (2020)
- Authors:
- USP affiliated authors: KALLAS, ESPER GEORGES - FM ; KALIL FILHO, JORGE ELIAS - FM
- Unidade: FM
- DOI: 10.1016/S1473-3099(20)30023-2
- Subjects: ANTICORPOS; IMUNOGENICIDADE DA VACINA; MÉTODO DUPLO-CEGO; VÍRUS DA DENGUE
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Lancet infectious diseases
- ISSN: 1473-3099
- Volume/Número/Paginação/Ano: v. 20, n. 7, p. 839-850, 2020
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
KALLÁS, Esper Georges et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet infectious diseases, v. 20, n. 7, p. 839-850, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1473-3099(20)30023-2. Acesso em: 01 jun. 2024. -
APA
Kallás, E. G., Precioso, A. R., Palacios, R., Thome, B., Braga, P. E., Vanni, T., et al. (2020). Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet infectious diseases, 20( 7), 839-850. doi:10.1016/S1473-3099(20)30023-2 -
NLM
Kallás EG, Precioso AR, Palacios R, Thome B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, Kalil Filho JE. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial [Internet]. Lancet infectious diseases. 2020 ; 20( 7): 839-850.[citado 2024 jun. 01 ] Available from: https://doi.org/10.1016/S1473-3099(20)30023-2 -
Vancouver
Kallás EG, Precioso AR, Palacios R, Thome B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, Kalil Filho JE. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial [Internet]. Lancet infectious diseases. 2020 ; 20( 7): 839-850.[citado 2024 jun. 01 ] Available from: https://doi.org/10.1016/S1473-3099(20)30023-2 - CD4+ T-cell activation impairs serogroup C Neisseria meningitis vaccine response in HIV-infected children
- Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine
- Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection
- Invariant natural killer T cells in patients with common variable immunodeficiency [Carta]
- IVIg Immune Reconstitution Treatment Alleviates the State of Persistent Immune Activation and Suppressed CD4 T Cell Counts in CVID
- CD57 Expression and Cytokine Production by T Cells in Lesional and Unaffected Skin from Patients with Psoriasis
- The CD8+ Memory Stem T Cell (TSCM) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection
- Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naive and DENV-Exposed Individuals in a Brazilian Cohort
- Short Communication: HIV Type 1 Subtype BF Leads to Faster CD4+ T Cell Loss Compared to Subtype B
- Broad and Cross-clade CD4+ T-Cell responses elicited by a DNA vaccine encoding highly conserved and promiscous HIV-1 M-group consensus peptides
Informações sobre o DOI: 10.1016/S1473-3099(20)30023-2 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
